This paper concerns the prevention of chronic kidney disease (CKD) following treatment for renal cell carcinoma (RCC). Over the last 10 years, partial nephrectomy has played an increasing role in the management of RCC, especially T1a disease. It has been...
The natural history of non-clear cell renal cell carcinoma (NCC-RCC) post-nephrectomy with curative intent remains poorly defined. The surveillance protocols are largely dependent on guidelines followed for clear cell RCC (CC-RCC). In this study, the authors evaluated the relapse patterns...
In recent years laparascopic partial nephrectomy (LPN) has emerged as an oncologically safe alternative to its radical nephrectomy counterpart. There is however a lack of consensus amongst the urology community regarding surveillance after LPN for patients with stage I tumours....
1 September 2017
| Paul Cleaveland, Vincent Tang
|
Urologic Oncology
Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...
In the May issue of BJUI Miki N Hew et al. discuss differences in renal function evolution between patients with renal cell carcinoma (RCC) submitted to radical nephrectomy (RN) and living kidney donors matched for age and gender. They also...
The incidence of renal cell carcinoma (RCC) in the UK has increased steadily over the last two decades, largely driven by the increasing use of abdominal imaging and the incidental detection of small renal lesions [1]. The majority of incidental...
Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...
This retrospective study over a 15-year period is to identify independent predictors of malignancy in Bosniak III (BIII) renal lesions and to build a prediction model based on identifiable clinical variables. These cysts, characterised by contrast-enhanced computed tomography (CECT), have...
This article reviews active surveillance (AS) in the management of small renal masses (SRM), the role of renal tumour biopsy (RTB), patient selection, tumour growth kinetics, and outcomes. SRMs which are defined as masses ≤4 cm in diameter and enhance...
With the rapid rise in incidental small renal mass detection, some of which have malignant potential, comes the need to either survey or treat these masses safely and with minimal morbidity. This large series of 147 patients with 171 masses,...
This event was submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and is awaiting CME approval. SIU ACADEMY BENCH TO BEDSIDE URO-ONCOLOGY GU CANCER TRIAD 7 November 0800-1130 AM EST – Bladder & Kidney Cancers 8 November...
Positive surgical margins (PSM) for solid organ malignancies are associated with adverse oncological outcomes. However, for RCC the prognostic significance of PSM after partial nephrectomies (PN) remains a matter of debate. As PN is more increasingly being used to excise...